Peptide LibraryGlutathione dosage in published studies and labels
These are the doses used for Glutathione in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Glutathione has human dosing evidence, but only by mouth. Randomised trials support oral doses of 250 mg once or twice daily, 500 mg once daily, and 250–1000 mg daily for raising body stores. The intravenous and intramuscular administration it is generally sold for in the peptide market has no controlled trial establishing a dose, and the skin-lightening claim it is sold on is contested in the dermatology literature.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 250–1000 mg daily, oral |
| Route | Oral (the only route with controlled trial dosing) |
| Frequency | Once or twice daily |
| Duration studied | Up to 6 months in the longest controlled trial |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Systematic review — oral glutathione for skin lightening and melasmaClinical trial · Systematic review of randomised controlled trials | Participants across five randomised controlled trials and one open-arm study | 250 mg once daily, 250 mg twice daily, or 500 mg once daily | Oral | Once or twice daily | — | Melanin index, versus placebo | Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025. |
| Oral supplementation RCT (Richie et al., 2015)Clinical trial · Randomised double-blind placebo-controlled trial | Non-smoking adults (n=54) | 250 mg or 1000 mg per day | Oral | Daily | 6 months | Glutathione stores in blood, erythrocytes, plasma, lymphocytes and buccal cells | Richie JP et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015. |
| Critical review — skin whitening claimsResearch-reported · Critical review | Review of the available human evidence | No established injectable dose identified | Various | — | — | Assessment of evidence quality for skin whitening | Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016. |
Where sources disagree
- Every dose above is oral. Glutathione is sold in the peptide market for intravenous or intramuscular injection, commonly at 600–2000 mg per session; no controlled trial establishes an injectable dose, and oral evidence does not transfer to injection.
- The skin-lightening effect the compound is marketed on remains contested in dermatology. The reviews cited above are explicit about small sample sizes and short follow-up, and one is titled around whether the claim is myth or verity.
- Glutathione appears as an outcome measure in thousands of trials of unrelated interventions, which inflates apparent evidence volume. Only studies that administer glutathione itself are counted here.